

Model-estimated annual rates (95% CI)

Favors
FF/UMEC/VI

Favors
UMEC/VI




Rate ratio (95% CI); p-value **Annual rate reduction, % (95% CI)**

On-treatment moderate/severe exacerbation

	FF/UMEC/VI	UMEC/VI		Rate ratio (95% CI); p-value	Annual rate reduction, % (95% CI)
Overall (n=5940)	0.87 (0.83, 0.91)	1.07 (1.01, 1.14)		0.81 (0.75, 0.88); p<0.001	19 (12, 25)
ICS use at screening (n=4232)	0.93 (0.88, 0.98)	1.21 (1.13, 1.30)		0.77 (0.70, 0.84); p<0.001	23 (16, 30)

On-treatment severe exacerbation

Overall (n=5940)	0.12 (0.11, 0.13)	0.17 (0.14, 0.19)		0.71 (0.59, 0.85); p<0.001	29 (15, 41)
ICS use at screening (n=4232)	0.13 (0.12, 0.15)	0.18 (0.16, 0.22)		0.71 (0.58, 0.88); p=0.001	29 (12, 42)



Rate ratio (95% CI)